Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2022

View Archived Issues

Modulating CYTOR promotes myogenesis in aging

TGFBR3L modulates FSH activity and fertility

Hemagglutinin anchor epitope unveiled as a target of broadly neutralizing antibodies

Compact cell classifiers packaged into AAV vectors for precision tumor cell targeting

MRSA superbug has prickly origins

French researchers patent new antibacterial compounds

Janssen Pharmaceutica discloses Mcl-1 inhibitors

Anaxis Pharma identifies new RIPK1 and/or MLKL inhibitors

Chinese researchers describe new GLP-1 receptor agonists

Life Biosciences to accelerate R&D activities on aging-related programs

Pfizer and BioNTech collaborate on mRNA-based vaccine to prevent shingles

Discovery of novel bergenin derivatives as immunosuppressive agents

Wigen Biomedicine Technology synthesizes new Wee1 inhibitors

RBT-0813 shown to neutralize Omicron and Delta variants of SARS-CoV-2 in live virus studies

Cystic Fibrosis Foundation award supports development of Peptilogics' PLG-0301 and PLG-0206

SalioGen obtains funding to advance research into genetic therapy for cystic fibrosis

Series A financing at ONK Therapeutics to support NK cell therapies through IND-enabling studies

Biomea's menin inhibitor BMF-219 normalizes glucose levels in animal models of type 2 diabetes

JUVA-019 enters preclinical development for inflammatory disease

LA-PAMAM/pmiR-218 polyplex as potential targeted gene therapy against HCC

Enanta expands respiratory virology program with EDP-323 for RSV

Regulating fibrin-neutrophil interaction for controlling periodontitis

Unity Biotechnology eyes IND-enabling studies with pipeline programs in 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...